3 completed, 2 terminated. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Terminated 2 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Stage II Small Lymphocytic Lymphoma: new trials by email Literature Review of Stage II Small Lymphocytic Lymphoma trials Research Report on Stage II Small Lymphocytic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 9 | 2010-04-01 | 2015-11-11 |
| Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Fludarabine Phosphate, Cyclophosphamide, Rituximab - Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2009-06-01 | 2020-02-25 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
Leukemia, Lymphocytic, Chronic, B-Cell (5) · Hodgkin Disease (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Mantle-Cell (3) · Waldenstrom Macroglobulinemia (3) · Burkitt Lymphoma (2) · Intraocular Lymphoma (2) · Lymphoma, Large-Cell, Immunoblastic (2) · Lymphoma, Non-Hodgkin (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Carcinoma, Hepatocellular (1) · Immunoblastic Lymphadenopathy (1) · Leukemia, Hairy Cell (1)
Chronic Disease (5) · Disease Attributes (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Leukemia (5) · Leukemia, B-Cell (5) · Leukemia, Lymphoid (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
Rituximab (4) · Cyclophosphamide (3) · Dasatinib (1) · Doxorubicin (1) · Etoposide (1) · Fenretinide (1) · Lenalidomide (1) · Prednisone (1) · Vincristine (1) · Vorinostat (1) · alvocidib (1) · cytokine inducible SH2-containing protein (1) · fludarabine phosphate (1)
National Cancer Institute (NCI) (3) · Fred Hutchinson Cancer Center (1) · University of Chicago (1)
United States (5)
Ajay Gopal (1) · John Sarantopoulos (1) · Joseph Flynn (1) · Mazyar Shadman (1) · Sonali Smith (1)
P30CA014599 (1), P30CA015704 (1), P30CA016058 (1), R21CA119519 (1), U01CA076576 (1), U10CA032102 (1), U10CA180888 (1)